Metyos, a pioneering medtech startup focused on addressing chronic kidney disease (CKD), has successfully raised €2.3M in a pre-seed funding round. The investment was led by Cenitz, with participation from KIMA Ventures, Advans Lab, and Bpifrance. The round also saw contributions from a network of doctors, health insurance angels, and business leaders from Implicity, Deepmind, and Nabla.
Frederic Picq, co-founder at Cenitz, expressed his enthusiasm for Metyos, citing the founding team’s impressive blend of entrepreneurial spirit and technical expertise as key factors driving the investment. “We see significant opportunity in Metyos not just because of its groundbreaking approach to CKD management, but because it represents the future of healthcare – a future where technology and the human experience come together to offer better, proactive care for all,” Picq added.
Advertisement
Innovating CKD Management with Biowearable Sensors
Metyos aims to revolutionize the management of chronic kidney disease through its biowearable sensor and platform, which provide real-time biomarker readings. This innovative approach allows doctors to monitor kidney function more effectively and empowers patients in their self-care journey. With CKD affecting 10% of the global population and being a major cause of death, Metyos’s technology seeks to proactively manage symptoms and slow disease progression, benefiting both patients and healthcare systems.
Founders’ Vision for a Healthier Future
Founded by CEO Alexandre Boulanger and CTO Olga Chashchina, Metyos is driven by a mission to transform the lives of over 800 million CKD patients worldwide. Boulanger, a serial medtech entrepreneur, previously founded Wandercraft, known for pioneering FDA-cleared and CE-marked lower limb exoskeleton technology. Dr. Chashchina brings her expertise in biosensors, combining a PhD in biomedical engineering with business acumen from McKinsey and an MBA.
Utilizing Funds for Wearable Technology Advancement
The funding secured by Metyos will be allocated towards advancing its wearable technology, focusing on progressing through clinical trials in preparation for FDA clearance. The company is actively recruiting participants for clinical trials to enhance and validate its biowearable technology.
“Our mission at Metyos is to move healthcare away from reactive care towards proactive disease management,” said co-founder Boulanger. “This funding, and the support and belief of the brilliant investors it brings with it, will help make this future a reality and help change the lives of so many patients and medical professionals worldwide.”
With this pre-seed funding, Metyos is well-positioned to make significant strides in the fight against chronic kidney disease, offering a new horizon of hope and improved care for millions of patients globally.
